Clinical lymphoma, myeloma & leukemia · 2026
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial.
СтатьяКлиническое исследование III фазыРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kristo Fjoralba, Mazerolle Flora, Alin Thibaud, Regnault Antoine, Ferdinandus Justin, Behringer Karolin, Jablonski Janina, Borchmann Peter, Ashaye Ajibade
Аннотация
INTRODUCTION: Patient-reported outcome (PRO) data were analyzed to explore the experience of chemotherapy-induced peripheral neuropathy (CIPN) symptoms by patients with newly-diagnosed advanced-stage classic Hodgkin lymphoma (AS-cHL) treated with BrECADD versus eBEACOPP, and explore the association of CIPN symptoms with health-related quality of life (HRQoL).
METHODS: Participants' experience was assessed during treatment and follow-up periods in a phase 3 trial of AS-cHL patients treated with BrECADD or eBEACOPP by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - core 30-item (QLQ-C30) questionnaire and the 20-item Chemotherapy-Induced Peripheral Neuropathy module (QLQ-CIPN20). Item responses were examined at each visit to describe the experience of CIPN symptoms per treatment arm. The association between patient-reported sensory symptoms and HRQoL was explored by describing PRO scores between participants with and without sensory symptoms.
RESULTS: Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence followed a similar pattern over time across arms: they were reported during the treatment period, before gradually decreasing post-treatment. Motor symptoms were less reported than sensory symptoms. Participants with sensory symptoms showed poorer overall health and physical function, as well asmore fatigue than those without.
DISCUSSION: These exploratory PRO analyses highlight the occurrence of CIPN-related sensory symptoms, and to a lesser extent, motor symptoms, of AS-cHL patients treated with multiagent regimens. Treatments such as BrECADD may be associated with fewer CIPN sensory symptoms, which could prevent detrimental effects on patients' HRQoL.
METHODS: Participants' experience was assessed during treatment and follow-up periods in a phase 3 trial of AS-cHL patients treated with BrECADD or eBEACOPP by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - core 30-item (QLQ-C30) questionnaire and the 20-item Chemotherapy-Induced Peripheral Neuropathy module (QLQ-CIPN20). Item responses were examined at each visit to describe the experience of CIPN symptoms per treatment arm. The association between patient-reported sensory symptoms and HRQoL was explored by describing PRO scores between participants with and without sensory symptoms.
RESULTS: Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence followed a similar pattern over time across arms: they were reported during the treatment period, before gradually decreasing post-treatment. Motor symptoms were less reported than sensory symptoms. Participants with sensory symptoms showed poorer overall health and physical function, as well asmore fatigue than those without.
DISCUSSION: These exploratory PRO analyses highlight the occurrence of CIPN-related sensory symptoms, and to a lesser extent, motor symptoms, of AS-cHL patients treated with multiagent regimens. Treatments such as BrECADD may be associated with fewer CIPN sensory symptoms, which could prevent detrimental effects on patients' HRQoL.